Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 6/20 | 0.45 |
| ▸ | NOS3 | P29474 | 5/20 | 0.45 |
| ▸ | NOS1 | P29475 | 5/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 4/20 | 0.40 |
| ▸ | ARG1 | P05089 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL27841789 | 1.00 | OTC (0.50) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL27562674 | 1.00 | OTC (0.50) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL344773 | 1.00 | OTC (0.50) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL27559277 | 1.00 | OTC (0.50) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL29227441 | 0.98 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL28208085 | 0.94 | OTC (0.46) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL26187286 | 0.94 | OTC (0.46) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL1668687 | 0.94 | OTC (0.46) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL2411547 | 0.93 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL7928810 | 0.93 | OTC (0.56) | OTCDDAH1NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314269-A1 | 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS | Global Bioenergies (FR) | 2024-02-07 | — | — | EP | claimed |
| WO-2022207684-A1 | 3-METHYLCROTONIC ACID DECARBOXYLASE (MDC) VARIANTS | GLOBAL BIOENERGIES (FR) | 2022-10-06 | — | — | WO | claimed |
| US-20210251963-A1 | UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 | SCANDION ONCOLOGY A/S (DK) | 2021-08-19 | — | — | US | claimed |
| EP-3846802-A1 | UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 | Scandion Oncology A/S (DK) | 2021-07-14 | — | — | EP | claimed |
| CN-105018443-B | A kind of epoxide hydrolase mutant and preparation method thereof | 浙江大学 | 2018-08-24 | — | — | CN | claimed |
| CN-108410839-A | A kind of beta-glucuronidase enzyme mutant that thermal stability improves | 北京理工大学 | 2018-08-17 | — | — | CN | claimed |
| US-8475792-B2 | Molecules with extended half-lives, compositions and uses thereof | MEDIMMUNE, LLC (US) | 2013-07-02 | — | — | US | claimed |
| EP-1588173-A2 | AFFINITY FISHING FOR LIGANDS AND PROTEINS RECEPTORS | Carlsberg A/S (DK) | 2005-10-26 | — | — | EP | claimed |
| WO-2004062553-A2 | AFFINITY SCREENING USING “ONE-BEAD-ONE-COMPOUND” LIBRARIES | CARLSBERG A/S (DK) | 2004-07-29 | — | — | WO | claimed |
| US-20040142379-A1 | Affinity fishing for ligands and proteins receptors | CARLSBERG RESEARCH LABORATORY (DK) | 2004-07-22 | — | — | US | claimed |
| WO-2003099322-A2 | IL-11 DERIVATIVES AND THERAPEUTIC USES THEREOF | ISIS INNOVATION LIMITED (GB) | 2003-12-04 | — | — | WO | claimed |
| CN-114149432-B | Dual CLK/CDK1 inhibitors for cancer treatment | 斯坦福国际研究院 | 2024-07-05 | — | — | CN | disclosed |
| US-20240182595-A1 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | GENZYME CORPORATION | 2024-06-06 | — | — | US | disclosed |
| CN-112513062-B | Oligonucleotide-containing small cell lung cancer therapeutic agent | 国立大学法人大阪大学 | 2024-05-10 | — | — | CN | disclosed |
| US-11964971-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-1296966-A | Polypeptide-human SR splicing factor 52 and polynucleotide for coding said polypeptide | BORONG GENE DEVELOPMENT CO LTD SHANGHAI (CN) | 2001-05-30 | — | — | CN | disclosed |
| EP-0927259-A1 | MODIFIED alpha-AMYLASES HAVING ALTERED CALCIUM BINDING PROPERTIES | GENENCOR INTERNATIONAL, INC. (US) | 1999-07-07 | — | — | EP | disclosed |
| CN-1189165-A | Imidazo [1,5 alpha ] pyridine derived serine protease inhibitors | AKZO NOBEL NV (NL) | 1998-07-29 | — | — | CN | disclosed |
| WO-1997043424-A1 | MODIFIED α-AMYLASES HAVING ALTERED CALCIUM BINDING PROPERTIES | GENENCOR INTERNATIONAL, INC. (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1996030398-A1 | NOVEL AUTO ANTIGEN | MURDOCH UNIVERSITY (AU) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182595-A1 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | UGGT1, B4GALT1, GALNT1 | OTC 3926/4885DDAH1 1119/4885NOS2 4805/4885 |
| US-11964971-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SF3B5 | OTC 4185/4885DDAH1 2142/4885NOS2 2388/4885 |
| US-20210251963-A1 | UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 | SRPK1, SRPK3, HNRNPK | OTC 554/4885DDAH1 1947/4885NOS2 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.